Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02207634 · ClinicalTrials.gov registry record · Phase 3
Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,974
- Enrollment target
NCT02207634: Completed Phase 3 study, sponsored by Amgen.
NCT02207634 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 1,974 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (156% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02207634, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,974 participants
- Enrollment target
Study Summary
This study evaluated change over time in neurocognitive testing in patients receiving statin therapy in combination with evolocumab (AMG 145), compared with patients receiving statin therapy in combination with placebo.
Primary Outcome
Assessments were performed with the Cambridge Neuropsychological Test Automated Battery (CANTAB), a language-independent battery of computerized tests that is used to assess cognitive function. The Spatial Working Memory (SWM) test assesses the cognitive domain of executive function (high-level thinking and decision making). Patients search for colored tokens hidden inside boxes on the screen by touching them. The critical instruction is that once a token has been found inside a box, there will
Interventions
- DRUG Placebo
- BIOLOGICAL Evolocumab
- DRUG Background Statin Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,974 participants |
| Start Date | 2014-09-10 |
| Est. Completion | 2016-11-11 |
| Phase | Phase 3 |
What the finished NCT02207634 record still lists
NCT02207634 is an interventional study that assigns participants to a tested intervention. Its 1,974 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (156% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02207634 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02207634 about?
NCT02207634 is a clinical study titled "Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects". This study evaluated change over time in neurocognitive testing in patients receiving statin therapy in combination with evolocumab (AMG 145), compared with patients receiving statin therapy in combination with placebo.
What is the current status of trial NCT02207634?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,974 participants. The study started on 2014-09-10. Estimated completion is 2016-11-11.
What interventions are being tested in trial NCT02207634?
The interventions under investigation include: Placebo (DRUG), Evolocumab (BIOLOGICAL), Background Statin Therapy (DRUG).
Who is sponsoring clinical trial NCT02207634?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02207634's enrollment target sits among peer trials
1,974 107th of 2000 higher than 1,894 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06062394 · 1,980 participants · NA
Penn Medicine Healthy Heart
- NCT07321886 · 1,980 participants · Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- NCT04251052 · 1,956 participants · NA
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI